INVESTOR ALERT: WGS Under Investigation by Pomerantz Law!

Company Background & Recent Allegations

GeneDx Holdings Corp. (NASDAQ: WGS) is a genetic testing company specializing in advanced genomic diagnostics for rare diseases (www.investing.com). The company’s stock was one of 2024’s best performers – surging over 2,500% that year – as investors cheered its rapid revenue growth and improving cash burn profile (www.investing.com). However, in early 2025 GeneDx came under intense scrutiny after Grizzly Research, a short-selling firm, published a report accusing the company of “actively committing widespread fraud” (www.prnewswire.com). Specifically, the report alleges GeneDx’s remarkable growth has been “largely an illusion, driven by fraudulent schemes and illegal tactics” to inflate revenue, including an illicit billing practice called “code stacking” to overcharge Medicaid/Medicare (www.investing.com). (Code stacking involves billing multiple procedure codes for tests in a way that doesn’t meet coverage criteria, a practice banned since 2013 (www.investing.com).) Grizzly’s report cited former employees and even a whistleblower lawsuit (previously undisclosed) as evidence that GeneDx has inflated its revenue by an estimated 25% via code stacking (www.investing.com). It also highlighted that GeneDx’s CEO Katherine Stueland and CFO Kevin Feeley have consistently sold their shares as soon as they vest – without making open-market purchases – which the report suggests is a red flag that insiders anticipate a serious company-threatening risk (www.investing.com).

These explosive allegations quickly led to shareholder rights firms announcing investigations. Pomerantz LLP, a prominent securities class-action law firm, disclosed it is investigating whether GeneDx and its executives engaged in securities fraud or other unlawful business practices (www.prnewswire.com). Similar investigations were launched by firms like Bronstein, Gewirtz & Grossman and Rosen Law, seeking investors who bought WGS shares to potentially form a class action (bgandg.com) (rosenlegal.com). The day Grizzly’s report released (Feb 5, 2025), WGS stock fell about 6.7% (closing at $67.18) on unusually high volume (www.prnewswire.com) (bgandg.com). Notably, this was a relatively modest drop given the severity of the claims, and the stock later rebounded – ending up significantly higher by late 2025. Nonetheless, the “Investor Alert” headlines underscore that GeneDx faces serious questions. The central issue is whether the company’s meteoric growth and recent profits are genuinely earned or propped up by improper billing and aggressive tactics. In the sections below, we examine GeneDx’s fundamentals – dividend policy, financial performance, leverage, valuation – and then discuss the risks, red flags, and open questions surrounding this situation.

Dividend Policy & Earnings Trajectory

GeneDx is a growth-oriented healthcare company that has never paid a cash dividend on its stock (financialreports.eu). In fact, its credit agreement with Perceptive (see below) explicitly restricts the payment of dividends (financialreports.eu), and management has stated that any future earnings will be reinvested to support operations and growth rather than returned to shareholders (financialreports.eu). Consequently, WGS carries a dividend yield of 0%, and income investors should not expect any near-term payouts. Traditional REIT metrics like FFO/AFFO are not applicable here, as GeneDx is not a REIT and until recently was not generating positive operating cash flows.

Financially, GeneDx has been transitioning from heavy losses toward breakeven. The company was born from a SPAC merger (Legacy Sema4) and the April 2022 acquisition of Legacy GeneDx, and it inherited significant costs. In 2021–2022, Sema4 incurred large losses (over $300 million net loss in 2022 alone) due to its expansive R&D and data platform ambitions. Starting in 2022, the company restructured aggressively – exiting non-core businesses (like women’s health and oncology testing) to focus on rare disease genomics (financialreports.eu). This, along with multiple rounds of layoffs (over 50% of staff cut per reports) and cost controls, started to curb the cash burn. By 2024, the financial improvements were evident: full-year 2024 revenue reached ~$300 million (boosted by one-time items) and on an adjusted basis GeneDx actually turned a profit of $9.4 million (non-GAAP) (www.advfn.com).

2025 saw a dramatic acceleration in reported performance. GeneDx’s full-year 2025 revenues jumped to $427.5 million – a 41% year-over-year increase (www.advfn.com) – driven largely by its core exome and whole-genome sequencing test business (which grew 54% YoY) (www.advfn.com). The company’s gross margins expanded to ~70% (adjusted) as it gained scale and shed lower-margin operations (www.advfn.com) (www.advfn.com). Importantly, GeneDx started showing bottom-line improvement: for 2025 it reported $41.8 million in adjusted net income (www.advfn.com). On a GAAP basis the firm still had a small net loss of $21.0 million in 2025 (due largely to stock-based compensation, amortization and other non-cash expenses) (www.advfn.com). But from a cash flow perspective, the turnaround is notable – GeneDx went from using $180M+ cash for operations in 2023 to generating positive operating cash flow in 2024, and continued that trend into 2025 (financialreports.eu). In the third quarter of 2025, for example, the company produced $8.8 million of free cash flow from operations (ir.genedx.com), and in Q4 2025 it generated another ~$5 million in operating cash inflow (www.advfn.com). This newfound financial footing (after years of losses) was a key factor in the stock’s huge run-up. It’s worth noting that these “adjusted” profits exclude substantial costs (over $60M of 2025 operating expenses were added-back items), so true GAAP profitability remains to be achieved. Still, by late 2025 GeneDx could credibly claim it was on a path to sustained positive cash flow – an achievement that many genomic testing peers have struggled to reach.

Leverage, Debt, and Coverage

GeneDx’s balance sheet carries manageable debt and ample liquidity, especially in light of its improved cash generation. The company has two primary debt obligations:

– Perceptive Term Loan ($50 million): In October 2023, GeneDx entered a credit facility with Perceptive Advisors for up to $75 M of senior secured term loans. It drew an initial $50 M Tranche A at closing (financialreports.eu) (financialreports.eu) (and although it became eligible for a $25 M Tranche B in 2024, the company chose not to draw the additional funding (financialreports.eu) (financialreports.eu)). The Perceptive loan matures in October 2028 and is interest-only until that maturity date (no principal amortization) (financialreports.eu) (financialreports.eu). It carries a floating interest rate of Term SOFR + 7.5% (financialreports.eu), which currently implies a roughly 12% annual interest rate given SOFR levels. Interest is paid monthly, and the rate would step up by +4% in event of default (financialreports.eu). As consideration for this loan, GeneDx also issued warrants to the lender (Perceptive) for 1.2 million shares of Class A stock, exercisable at a high strike price (post-reverse-split) (financialreports.eu) (financialreports.eu). As of year-end 2024, the term loan’s outstanding balance was about $55.8 M (net of issuance costs) and no principal payments are due until the 2028 balloon payment (financialreports.eu) (financialreports.eu).

– Connecticut DECD Loan (~$5.8 million): This is a low-interest development loan originally provided to support Sema4’s lab in Connecticut, which has been partially forgiven over time. In 2017, the Connecticut Department of Economic & Community Development (DECD) extended up to $15.5 M, contingent on job creation milestones (financialreports.eu) (financialreports.eu). As GeneDx struggled, the state amended the loan in 2023: GeneDx paid a $2.0 M lump sum and DECD forgave $2.8 M of principal for achieved milestones (financialreports.eu) (financialreports.eu). As of Dec 31 2024, the remaining loan balance was $5.8 M (financialreports.eu). The loan carries only a 2.0% interest rate and had interest-only payments through mid-2024; starting August 2024, GeneDx must make monthly principal + interest payments through July 2029 (financialreports.eu). The payment schedule is relatively light (roughly $1 M per year). Notably, DECD had forgiven a total of $7.3 M by 2024 under this program (and up to $12.3 M could be forgiven if all goals were met) (financialreports.eu) (financialreports.eu) – essentially a taxpayer subsidy to the company.

Aside from these loans, GeneDx has significant lease obligations (for lab facilities, office space, and equipment). As of year-end 2024, it reported $62.3 M in future minimum payments for operating leases and $31.9 M for finance leases (financialreports.eu) (financialreports.eu), totaling around $94 M over the coming years. This is a material fixed cost, though the company has been consolidating sites after shutting down Legacy Sema4 operations.

On the liquidity side, GeneDx’s financial position is strong relative to its debt. The company ended 2025 with $172.3 M in cash and equivalents (plus $66.3 M in marketable securities) on the balance sheet (www.advfn.com) (www.advfn.com) – roughly $238 M in total liquidity. This cash stockpile was bolstered by successful capital raises: GeneDx conducted an equity offering in early 2023 (netting ~$143 M) (financialreports.eu) (financialreports.eu) and later implemented an at-the-market (ATM) stock sale program. In Q4 2025 alone, it sold ~147,600 shares via the ATM at high prices, raising $21.1 M net (www.advfn.com). The company used $10 M of cash in that quarter to make a scheduled legal settlement payment (more on that below) (www.advfn.com), but still generated positive net cash. Overall, net debt is negative – in other words, cash on hand exceeds total debt outstanding by a wide margin.

Coverage: With the business nearing EBITDA breakeven, GeneDx’s interest obligations are currently well-covered. The Perceptive loan’s interest runs roughly ~$6 M per year (12% of $50 M), and the DECD loan interest is negligible (~$0.1 M per year). By Q3 2025, GeneDx had achieved $36.4 M in operating cash flow for the first nine months of 2025 (ir.genedx.com), which comfortably exceeds the annual interest burden. Free cash flow turned positive in 2024 and was +$8.8 M in Q3 2025 alone (ir.genedx.com). Even using GAAP metrics, interest expense (~$4.8 M for first 9 months of 2025) was a small fraction of gross profit. Thus, interest coverage does not appear to be a near-term problem – a dramatic change from a year or two ago when the company was deeply cash-flow negative. The debt maturities are also favorable: no principal due on the big loan until late 2028, and only ~$1 M/year on the state loan through 2029 (financialreports.eu). This gives GeneDx breathing room to execute its growth plan provided its financial statements are accurate. It’s worth mentioning that the Perceptive loan covenants include restrictions (e.g. on additional indebtedness, liens, asset sales, and dividends) (financialreports.eu) (financialreports.eu), but thus far GeneDx has remained in compliance and even forewent additional borrowing it was entitled to. In short, the leverage profile seems prudent for a growth company – if the reported earnings and cash flows are reliable. The big unknown is whether any outcomes of the fraud allegations (such as potential repayments or fines) could impair this picture (we discuss this under Risks below).

Valuation & Peer Comparison

Despite being a mid-cap healthcare company with persistent GAAP losses, GeneDx’s stock has been valued at growth tech-like multiples. In early 2025 (prior to the short-seller saga), GeneDx’s market capitalization was about $2 billion (www.investing.com) – nearly 7× the $330 M price that OPKO Health sold GeneDx for in mid-2022 (www.investing.com) (www.investing.com). By late 2025, the market cap swelled to around $4 billion as the share price climbed into the triple digits (www.google.com). At ~$4 B, WGS was trading at roughly 9× its 2025 revenues ( ~$427 M ) (www.advfn.com). That is a rich valuation on a price-to-sales basis, significantly higher than most diagnostic lab companies or biotech firms. Even using GeneDx’s adjusted net income (~$42 M in 2025), the stock’s price-to-earnings ratio would exceed 95× – and on a GAAP earnings basis the P/E is negative (since GAAP net loss is still ongoing). In fact, Google Finance showed WGS’s trailing P/E at an eye-popping 2,233 (likely due to negligible trailing earnings) (www.google.com), underscoring that the valuation is not grounded in traditional earnings multiples. Investors have essentially been pricing GeneDx for sustained high growth and eventual significant profitability.

For context, other genetic testing and diagnostics peers have struggled to command anything close to WGS’s multiples. Invitae (NVTA), once a high-flying competitor in genetic testing, saw its market cap collapse to a few hundred million dollars by 2023 after never turning an annual profit and accumulating over $6 B in losses since inception (36kr.com). Invitae’s revenue in 2023 was around $516 M (36kr.com) (comparable to GeneDx’s scale), yet NVTA stock trades at roughly ~0.5× sales (in part due to bankruptcy concerns), a far cry from GeneDx’s 9× sales. Another peer, 23andMe (ME), has seen its stock price plummet ~98% from its highs, with its market value shrinking from ~$5–6 B to nearly zero (www.jiemian.com). The broader genomic testing sector has been riddled with unprofitable business models and falling investor sentiment – many “genomics revolution” companies that went public via SPACs or IPOs in 2020–21 are down 80–90% from their peaks. GeneDx, in contrast, became an outlier success story in 2024–2025, delivering rapid growth and approaching breakeven while others faltered. This divergence in performance helped justify a premium valuation for WGS, but it also raises skepticism. If GeneDx truly has a sustainably superior model or proprietary advantage (e.g. its rare disease data prowess), a premium is warranted – however, if its results were juiced by one-time maneuvers or risky practices (as the short-seller contends), the valuation could prove very fragile.

It’s also instructive to compare GeneDx’s valuation to more established diagnostic companies. For instance, Quest Diagnostics (DGX) and Labcorp (LH) – large clinical lab firms – tend to trade around 2–3× sales and 12–15× earnings in recent years. GeneDx, even after the recent pullback, is dramatically above those levels by sales multiple, despite being much smaller and riskier. Part of the bull thesis for WGS is that it isn’t just a lab test company – it markets itself as a health data/AI company too, which can attract software-like valuation multiples. Indeed, in the SPAC-era pitch, Sema4/GeneDx touted its big-data platform (Centrellis) and massive genomic database as key assets, suggesting a future of AI-driven healthcare insights (a narrative akin to tech companies) (www.investing.com). Management continues to emphasize a “compounding data advantage” from its database of rare disease genomes (www.advfn.com). Such story elements likely contributed to investors assigning a high revenue multiple, on the assumption that GeneDx might one day monetize its dataset or enjoy winner-take-all network effects in rare disease diagnostics. However, as discussed below, there are questions about how real or defensible this data-driven moat is.

In summary, WGS’s valuation has been lofty. At its 2025 peak, the stock price (over $130) reflected tremendous optimism about GeneDx’s growth trajectory and competitive edge. The ongoing investigations and allegations cast a shadow on that optimism. If growth slows or if any financial restatements/legal liabilities emerge, there is substantial downside risk given the rich valuation starting point. Conversely, if GeneDx can conclusively refute the fraud claims and continue growing ~30%+ annually, the stock’s premium may be justified (or even expand). Investors should weigh these valuation extremes in light of the significant uncertainties noted below.

Risks, Red Flags & Open Questions

Multiple red flags have surfaced around GeneDx, and the situation presents a number of unresolved questions for investors. We outline the key risks and issues here:

– Alleged Revenue Inflation: The crux of Grizzly Research’s short thesis is that GeneDx’s revenue growth has been artificially inflated. Former employees claim the company engages in “code stacking” – billing insurers for multiple test codes improperly – which could overstate revenue by ~25% (www.investing.com). Code stacking of genetic tests is illegal (banned since 2013) (www.investing.com). If this allegation is accurate, a significant portion of GeneDx’s recent sales may not be sustainable or could even be clawed back by payors. In fact, Grizzly anticipates that Medicare, Medicaid, and private insurers will seek reimbursement for past overpayments tied to these practices (www.investing.com). This exposes GeneDx to potential liability: refunds, penalties, or fines that could total tens of millions of dollars. A related red flag is that in 2022 GeneDx (as Sema4) quietly agreed to repay $42 M to a large insurer (UnitedHealthcare) over four years (www.investing.com). The company did disclose this settlement in its filings (financialreports.eu) (financialreports.eu), but according to the short report it failed to reveal that the dispute was specifically over fraudulent billing (code stacking). The remaining payments on that settlement are relatively small (GeneDx had $12 M left to pay as of end-2024 (financialreports.eu), with the last installment due by mid-2026), but the key issue is why those overpayments happened and whether the practice persisted. The allegations suggest that even after the UHC settlement, GeneDx continued the same coding tactics, raising serious compliance and management integrity concerns.

– Regulatory & Legal Exposure: The content of the whistleblower action referenced by Grizzly is not yet public, but it reportedly accuses GeneDx of running illicit “independent counselor” units to funnel patients to its tests (www.investing.com). Such a scheme could violate anti-kickback or patient referral laws. If a qui tam (whistleblower) lawsuit has indeed been filed under the False Claims Act, the U.S. Department of Justice (DOJ) could be investigating GeneDx. Industry sources cited by Grizzly indicate the DOJ has intensified its crackdown on Medicare/Medicaid fraud in diagnostics, with over $800 M in fines issued recently to offenders (www.investing.com). GeneDx could become “next in line” for a hefty fine or federal action (www.investing.com). Moreover, multiple shareholder law firms (Pomerantz, Rosen, Bronstein, Scott+Scott, Schall, etc.) are circling, which often precedes a class-action lawsuit on behalf of investors if evidence emerges that the company misled investors or violated securities laws (www.prnewswire.com) (bgandg.com). In short, GeneDx faces battles on two legal fronts – regulatory (government/insurer claims) and securities litigation. The outcomes are uncertain, but any of these could result in financial damages, management upheaval, or reputational harm. Notably, GeneDx has so far declined to comment publicly on the short-seller allegations (seekingalpha.com), which some investors interpret as worrisome silence, though the company may be in a quiet period or awaiting counsel guidance. An open question is whether an internal investigation is underway at GeneDx and if the findings (if any) will be disclosed. Investors should monitor any SEC filings or statements for hints of regulatory inquiries (e.g. subpoenas, DOJ interest) – none have been confirmed publicly as of now, but the risk is clearly on the table.

– Insider Trading & Governance: A striking red flag is the insider trading pattern. CEO Katherine Stueland and CFO Kevin Feeley have consistently sold virtually 100% of their vested shares immediately upon vesting (www.investing.com). According to the short report and insider filings, neither has ever purchased WGS stock on the open market – their ownership increases only via granted equity, which they then monetize at first opportunity (www.investing.com). While insiders selling stock doesn’t prove anything (executives often sell for personal diversification), the total lack of any insider buying, even during periods of optimism, can signal that management might lack confidence in the long-term value or knows of risks not obvious to the public. The timing is also notable: these accelerated insider sales occurred throughout 2024 as the stock was skyrocketing, and even around the time of upbeat announcements. Shareholders have to ask: if GeneDx’s prospects are truly bright and its accounting is clean, why are its top leaders consistently cashing out? This behavior “suggests insiders may be aware of an imminent risk that will significantly impact the company,” Grizzly posited (www.investing.com). Furthermore, GeneDx’s board of directors and audit committee will be under the microscope regarding oversight. Did they have knowledge of the billing practices? Were proper compliance controls in place? If governance is weak (as implied by reports of insular management and “favoritism” toward certain employees (cn.investing.com)), there’s risk that the company’s culture enabled cutting corners to meet aggressive growth targets.

– Business Model and Competitive Advantage: Setting aside the fraud claims, there are broader strategic questions about GeneDx’s business. The company’s initial pitch included building a powerful health data platform (Centrellis) in partnership with the Mount Sinai Health System. However, according to former insiders, Centrellis was “smoke and mirrors” – an overhyped analytics platform that never delivered and was quietly discontinued (www.investing.com). Achieving what was promised for Centrellis would have required “billions of dollars and many years” of work, which the company didn’t have (www.investing.com). Sema4/GeneDx likely promoted the image of being a “data/AI company” to command a higher valuation multiple (www.investing.com). Now in 2025, management talks up a new concept called GeneDx Infinity™ – presumably an AI-driven continuous data network gleaned from their database. The question is: is this real or marketing vapor? Skeptics note that Mount Sinai, which was a key source of data, has distanced itself from GeneDx after the rebranding (www.investing.com). Without Mt. Sinai’s 12 million patient records feed and with Centrellis gone, can GeneDx truly create a differentiated genomic data platform? Some clinical geneticists have expressed doubt that GeneDx’s diagnostic tests are meaningfully more accurate or insightful than competitors’, suggesting the company “lacks any sustainable competitive advantage” aside from having a large test volume (grizzlyreports.com) (grizzlyreports.com). GeneDx does have a respected legacy (the original GeneDx was a pioneer in rare disease genetic testing) and a large database of exomes, but other firms also have sizeable genomic datasets. If the only way GeneDx beat peers like Invitae was by aggressive billing or underpricing, its edge could evaporate. Investors need clarity on how GeneDx plans to monetize its data (Pharma partnerships? Improved test reports? New products?) and whether that strategy is credible. At present, the bull narrative is that GeneDx’s scale in rare disease testing will let it lean into higher-margin data services or drug discovery support. The bear narrative is that this is mostly hype, and the core lab business will face pricing/reimbursement pressures over time. This conflict remains unresolved – upcoming earnings calls and presentations will be important to gauge whether “data” is translating into revenue streams or if it’s still mainly a story.

– Industry and Macro Risks: GeneDx also operates in a challenging external environment. The genetic testing industry has been notoriously unprofitable, and many once-promising companies have imploded. We discussed Invitae and 23andMe’s troubles; their falls from grace show how quickly sentiment can reverse in this sector. Insurance reimbursement for genetic tests is notoriously complex and can change with little notice – for example, if payors decide to bundle genetic testing codes or tighten medical necessity criteria, companies like GeneDx could see lower realized pricing. In fact, the UnitedHealthcare lawsuit that led to GeneDx’s $42 M settlement was part of a broader crackdown by insurers on lab billing schemes (news.bloomberglaw.com). Additionally, regulatory oversight of lab-developed tests (LDTs) is increasing, and any future FDA or CMS rules could raise the bar (and cost) for compliance. GeneDx is also subject to general macroeconomic conditions – as a still cash-consuming growth firm (if we include capital needs for expansion), it relies on access to capital. The company’s ability to raise cash at favorable terms (e.g., the ATM program in 2025) could be hampered if its stock price remains depressed or if credit markets tighten. It’s positive that GeneDx has a decent cash runway (over $200 M liquid assets) (www.advfn.com); however, rapid growth may require continued investment in R&D, marketing, and possibly acquisitions. If the fraud allegations scare away partners or lead to stricter audit controls by insurers, GeneDx’s growth might slow just as it has guided for ~$540–$555 M in 2026 revenue (www.advfn.com) (www.advfn.com) (33–35% growth). In short, execution risk is high – GeneDx must prove it can organically grow test volumes >30% annually while staying on a profitable trajectory and operating squeaky-clean. That’s a tall order in the best of times, let alone under a cloud of investigations.

Open Questions: There are several critical questions that remain unanswered at this point, which investors should be asking: (1) How much of GeneDx’s recent revenue growth was driven by legitimate demand versus potentially unsustainable billing practices? If the company were forced to stop “code stacking” entirely (assuming it occurred), would growth fall by ~25% or more? Management has not broken out how much revenue comes from Medicaid/Medicare versus commercial insurers – but if a significant portion is government payors, the clawback risk is higher. (2) What internal controls and audits does GeneDx have around coding and billing? Given the historical issue with UnitedHealth and the whistleblower claims, one would expect the board to commission an independent audit of billing practices. No word yet on this – transparency on any findings will be key to regaining trust. (3) Will GeneDx’s management or board publicly refute the short seller allegations point-by-point? Thus far, they have remained relatively silent, which might be strategic, but silence can allow fear to fester. Investors will want to see either a strong rebuttal or tangible actions (like executive changes or remediation plans) if there’s merit to any claims. (4) What is the status of the whistleblower lawsuit and could the DOJ or OIG be secretly investigating? Often, in False Claims Act cases, the DOJ’s involvement is only revealed when they decide whether to join the suit. Any indication of federal investigation (even a subpoena) would be material to disclose. This is a wildcard that could drop unexpectedly. (5) How stable are GeneDx’s relationships with key stakeholders (patients, insurers, hospitals) in light of these accusations? If clinicians or genetic counselors begin avoiding GeneDx due to reputational concerns, or if insurers increase scrutiny/denials of its claims, the growth could stall independent of legal outcomes. On the flip side, if GeneDx’s test quality and turnaround remain strong, perhaps clients stick with them. Monitoring test volume trends (which the company reports quarterly) will be important – any sudden slowdown might hint at an impact from these issues. (6) Is GeneDx’s “data platform” initiative genuine this time? The company touts its genomic database as a long-term differentiator. Investors should look for evidence of revenue from data collaborations or software products (for instance, partnerships with pharma for drug discovery, or licensing deals around its database). If nothing concrete materializes in 2024–2025 beyond selling lab tests, one must question the lofty tech-like valuation.

In conclusion, GeneDx (WGS) presents a high-risk, high-reward profile at this juncture. On one hand, the company operates in an exciting field with real needs – faster diagnosis of rare genetic diseases – and it has shown an ability to scale revenue rapidly while inching toward profitability. On the other hand, the cloud of fraud allegations and legal investigations cannot be ignored. Investors are alerted to the possibility that some of GeneDx’s success may have been built on dubious foundations, which, if true, could unravel the story quickly. Pomerantz Law’s investigation, alongside others, indicates that the shareholder community is on edge. Until more information comes to light (either through the legal process or company disclosure), WGS will likely trade on rumor and sentiment. Due diligence and caution are paramount. Potential investors should demand clarity from management and closely watch for any developments from regulators. The coming quarters will be telling – either validating GeneDx’s growth story or exposing significant cracks. Given the stakes, we echo the “Investor Alert” sentiment: approach WGS with eyes open to the risks, and be prepared for volatility as this story unfolds (www.prnewswire.com) (www.investing.com).

Sources: GeneDx SEC filings (10-K) (financialreports.eu) (financialreports.eu); GeneDx investor press releases (www.advfn.com) (www.advfn.com); Grizzly Research report (Feb 5 2025) (www.investing.com) (www.investing.com); Pomerantz Law announcement (www.prnewswire.com); Bronstein LLP notice (bgandg.com); Investing.com news (www.investing.com); 36Kr/WSJ analysis (36kr.com) (www.jiemian.com); etc.

For informational purposes only; not investment advice.